Evidence map›Paper›PMID 40238288›Full record

ArticleInternational journal of environmental research and public health2025

Influence of CYP2C8 Polymorphism on the Exposure to Chloroquine in Patients with Malaria by

Luann Wendel Pereira de Sena, Hellen Thais Fuzii, Fabiola Elizabeth Villanova, Amanda Gabryelle Nunes Cardoso Mello, Maria Pantoja Moreira de Sena, Michelle Valéria Dias Ferreira, José Luiz Fernandes Vieira

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of environmental research and public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Luann Wendel Pereira de SenaCollege of Collective Health, Federal University of the South and Southeast of Para, Cidade Universitaria, Avenida dos Ipês s/n, Maraba 68500000, Para, Brazil.ORCID 0000-0001-9363-5766
Hellen Thais FuziiTropical Medicine Center, Para Federal University, Generalissimo Deodoro Street 92, Belem 66074740, Para, Brazil.ORCID 0000-0002-0616-3543
Fabiola Elizabeth VillanovaTropical Medicine Center, Para Federal University, Generalissimo Deodoro Street 92, Belem 66074740, Para, Brazil.
Amanda Gabryelle Nunes Cardoso MelloPharmacy Faculty, Para Federal University, Campus Universitario do Guama, Augusto Correa Street 01, Belem 66074740, Para, Brazil.
Maria Pantoja Moreira de SenaPostgraduate Program in Tropical Diseases, Para Federal University, Generalissimo Deodoro Street 92, Belem 66074740, Para, Brazil.
Michelle Valéria Dias FerreiraPharmacy Faculty, Para Federal University, Campus Universitario do Guama, Augusto Correa Street 01, Belem 66074740, Para, Brazil.
José Luiz Fernandes VieiraPharmacy Faculty, Para Federal University, Campus Universitario do Guama, Augusto Correa Street 01, Belem 66074740, Para, Brazil.ORCID 0000-0003-4842-8762

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the impact of the CYP2C82 polymorphism on chloroquine and desethylchloroquine concentrations in patients with malaria caused by

methodsA prospective study was conducted on patients with malaria in an endemic area of the Amazon basin. Liquid chromatography was employed to measure the levels of chloroquine and desethylchloroquine, while molecular methods estimated the frequency of the CYP2C82 variant.

resultsThis study revealed that plasma levels of chloroquine were higher in patients with the CYP2C82 polymorphism compared to those without this variant. The difference in plasma levels ranged from 5% to 26.5%. Conversely, patients with the CYP2C82 polymorphism exhibited lower levels of desethylchloroquine.

conclusionThe findings of this study confirm the impairment of chloroquine metabolism by the CYP2C82 variant. However, it is noteworthy that in the dose regimen used for malaria treatment, these changes did not lead to toxic concentrations of the drug.

Indexed as

AntimalarialsChloroquineCytochrome P-450 CYP2C8Malaria, VivaxPolymorphism, GeneticAdolescentAdultBrazilFemaleHumansMaleMiddle AgedPlasmodium vivaxProspective StudiesYoung AdultAntimalarialsChloroquineCYP2C8 protein, humanCytochrome P-450 CYP2C8desethylchloroquinechloroquinemalariaPlasmodium vivaxpolymorphism

Identifiers

PMID40238288
PMCPMC11941787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.